Fig. 6
From: RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Therapeutic approaches to target RAS in cancer. This includes various strategies to target RAS mutations, particularly: KRASG12C Inhibitors: Data from clinical trials demonstrate their efficacy; KRASG12D Inhibitors: Targeting this specific mutation to provide therapeutic benefit; KRASG12V Inhibitors: Developing agents to inhibit this variant effectively; Multi-KRAS Inhibitors: Agents designed to target multiple KRAS mutations simultaneously; Pan/Multi-RAS Inhibitors: Broader inhibitors that target various RAS isoforms and mutations; Immune Therapies: Approaches that harness the immune system to target RAS-driven tumors. These diverse therapeutic strategies aim to improve outcomes for patients with RAS-mutant cancers